SOURCE: OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals, Inc.

May 30, 2017 11:41 ET

OncBioMune Receives Approval for Male Fertility Product in Mexico

BATON ROUGE, LA--(Marketwired - May 30, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that the registration of the male fertility product Andfrt® has been approved by the Mexican Ministry of Health. OncBioMune has rights to Andfrt® for the Mexican market through an exclusive license agreement with QPharma, Inc. QPharma markets the product in Europe under the brand name Androferti®.

Andfrt®, a unique twice daily supplement, is a male fertility product containing an exclusive and balanced formula composed of L-Carnitine, antioxidants, vitamins and minerals. When taken for 3-6 months, clinical studies show that Andfrt® can improve sperm mobility, concentration and reduce sperm fragmentation.

Manufacturing of the first lot of Andfrt® is underway, with product launch expected late in the third quarter of 2017. OncBioMune's marketing efforts will be focused on urologists and fertility clinics across the country. Based upon the success of Androferti in Europe, the Company anticipates revenue from Andfrt® of approximately US$150,000 from launch to the end of 2017 and over $500,000 in the first full year of sales.

"We are excited about another approval from Mexico's Ministry of Health, which paves the way for our third product in the Mexican markets," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "Sales of Bekunis® and Cirkused® are constantly growing and with the addition of Androferti, we're on track for a solid 2017. Androferti is a popular fertility supplement in Europe and our research indicates that the product will be warmly received in Mexico as well. Next in queue is our Anti-D immunoglobulin product as we continue to build our footprint to become a household brand with a diverse portfolio of approved products in Mexico.

More information on Androferti can be found at http://androferti.co.uk.

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information

  • INVESTOR AND MEDIA CONTACT:
    OncBioMune Pharmaceuticals, Inc.
    Andrew Kucharchuk
    President and Chief Financial Officer
    akucharchuk@oncbiomune.com